文/梧桐小新 近日，华扬联众数字技术股份有限公司（ST华扬，603825）披露关于公司及相关人员收到北京证监局《行政处罚事先告知书》的公告。经查，华扬联众未按规定 披露控股股东、实际控制人18,153万元非经营性资金占用事项，导致相关定期报告存在重大遗漏；少计提对北京鑫诺科捷商贸有限公司应收账款的坏账准备，导致 2021年、2022年年度报告分别虚增利润总额1,732.96万元、6,939.31万元。北京证监局拟对华扬联众处以500万元的罚款，对2名相关责任人分别处以750万元、200 万元的罚款。 同日，华扬联众还披露关于实施其他风险警示暨停牌的公告。公司股票于2025年8月25日停牌1天，2025年8月26日起实施其他风险警示，股票简称由"华扬联众"变 更为"ST华扬"。 一、1.82亿资金占用被罚 《行政处罚事先告知书》显示，华扬联众涉嫌违法的事实如下： 1、华扬联众未按规定披露控股股东、实际控制人非经营性资金占用事项，导致相关定期报告存在重大遗漏 2021年，华扬联众及其全资子公司北京华扬创想广告有限公司通过北京嘉实兆丰投资管理有限公司累计向华扬联众控股股东、实际控制人苏同提供资金18,153万 元， ...

登录新浪财经APP 搜索【信披】查看更多考评等级 专题：泰禾集团董事长黄其森因涉嫌违法被实施留置 每经编辑|张锦河 8月22日，泰禾集团股份有限公司公告，董事会于近日获悉，公司董事长兼总经理黄其森因涉嫌违法被辽宁省新民市监察委员会实施 留置措施。截至本公告披露日，公司存在资产被冻结、查封的情况，会对公司运营产生一定影响。除此之外，公司按原组织架构和 管理体系在正常运转，各项经营活动仍然正常进行。 公司同日披露，公司及相关当事人收到中国证监会福建监管局行政处罚决定书。依据《中华人民共和国证券法》的有关规定，福建 证监局对泰禾集团信息披露违法违规行为进行了立案调查。本案现已调查、办理终结。 经查明，当事人存在以下违法事实： 二、泰禾集团2020年至 2022年年度报告存在重大遗漏 一、泰禾集团未按规定披露重大诉讼 2020年7月6日至2022年12月13日，泰禾集团系深圳证券交易所上市公司和"16 泰禾 02""16 泰禾 03""17 泰禾 01""17 泰禾 02""18 泰禾 01""18 泰禾 02"等6只债券发行人（以下简称债券发行人）。 2020年7月6日至2021年5月8日，泰禾集团发生13起诉讼， ...

今日晚间，泰禾集团股份有限公司公告称，公司董事会于近日获悉， 公司董事长兼总经理黄其森先生因涉嫌违法被辽宁省新民市监察委员会实施留 置措施。 2020年7月6日至2022年12月13日，泰禾集团系深圳证券交易所上市公司和"16泰禾02""16泰禾03""17泰禾01""17泰禾02""18泰禾 01""18泰禾02"等6只债券发行人（以下简称债券发行人）。 2020年7月6日至2021年5月8日，泰禾集团发生13起诉讼，标的额累计达967,369.95万元，占公司2020年经审计净资产的48.21%，其中 有12起诉讼的标的额超5,000万元；2021年12月14日至2022年12月13日，泰禾集团发生10起诉讼，标的额累计达619,060.73万元，占 公司2021年经审计净资产的41.84%，其中有9起诉讼的标的额超5,000万元。 泰禾集团应当及时披露前述诉讼，但公司迟至2023年5月26日仅披露其中1起诉讼，其余22起诉讼至2025年2月6日才陆续披露完毕，不符 合《证券法》第七十八条第一款、第八十条第一款和第八十一条第一款的规定。 二、泰禾集团2020年至2022年年度报告存在重大遗漏 泰禾集团作为 ...

为健全资本市场基础制度，加强投资者权益保护，8月20日，上海金融法院与上海证监局联合发布十个 涉证券虚假陈述案例。 证券时报记者获悉，本次发布的十个案例，包括五个证券虚假陈述责任纠纷金融审判典型案例及五个信 息披露违法行为行政监管执法案例，充分体现了加大立体追责力度，加强资本市场诚信建设的共同立 场。案例涉及参与资本市场各方主体，通过更精准的事实认定和规则适用，充分彰显了打击各类信披违 法行为、净化资本市场生态的鲜明态度。案例还积极回应资本市场法治新需求，明确了司法和监管对信 息披露领域新问题和新现象的态度，充分展示了强化资本市场主体规则预期、提供更加及时有效规则供 给的坚定决心。 其中，上海金融法院发布了近年来审理的五个证券虚假陈述责任纠纷案例，旨在向金融市场提供明确规 则指引，持续提升资本市场法治化水平。案例呈现以下特点：一是准确认定证券虚假陈述行为。证券虚 假陈述责任纠纷取消行政前置程序之后，发行人是否构成虚假陈述行为成为新的争议焦点。本次发布的 案例涉及准确适用"预测性信息安全港规则"，明确预测性信息的识别原则及免责边界，强调上市公司等 信息披露义务人不得借"预测性"之名逃避应履行的信息披露义务，依法 ...

Core Viewpoint - The resignation of Vice President Hua Songyuan and ongoing investigations into alleged fraudulent securities issuance have negatively impacted the stock price and financial performance of Sichuang Medical Technology Co., Ltd. (思创医惠) [1][4] Group 1: Management Changes - Vice President Hua Songyuan resigned for personal career planning reasons and will no longer hold any position in the company after his resignation [1] - Hua's original term was set from December 6, 2024, to December 5, 2027 [1] Group 2: Financial Performance - Sichuang Medical has reported continuous net losses, with net profits of -878 million yuan in 2022, -874 million yuan in 2023, -502 million yuan in 2024, and -19.56 million yuan in the first quarter of 2025 [3] - The company has faced significant discrepancies in its financial disclosures, leading to regulatory scrutiny and penalties [2][4] Group 3: Legal Issues - The company is under investigation by the Hangzhou Public Security Bureau for alleged fraudulent securities issuance, with evidence being collected [1][4] - In January 2024, the company received administrative penalties from the China Securities Regulatory Commission for fabricating significant false content in public offering documents, resulting in inflated revenues and profits [4][5][6] - The company was fined 81.7 million yuan for the fraudulent activities, and its former chairman was banned from the market for 10 years [6] Group 4: Business Operations - Sichuang Medical operates in two main business segments: business intelligence and smart healthcare, providing IoT solutions for various industries [2] - The company has recently sold its 100% stake in a subsidiary, Medical Technology Co., Ltd., to alleviate financial burdens due to ongoing losses [6]

证券代码：000851 证券简称：*ST 高鸿 公告编号：2025-085 大唐高鸿网络股份有限公司 关于收到中国证券监督管理委员会《行政处罚事先告知书》及 重大违法强制退市风险提示公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 特别提示： 规，被中国证券监督管理委员会(以下简称"中国证监会")立案调查。公司于 2025 年 8 月 8 日收到中国证监会下发的《行政处罚事先告知书》(以下简称"《告知 书》")。根据《告知书》认定的事实，公司 2020 年非公开发行股票构成欺诈发 行、2015 年至 2023 年年度报告存在虚假记载，将触及《深圳证券交易所股票上 市规则》第 9.5.1 条第一项、第 9.5.2 条第一款第（六）项规定的重大违法强制 退市情形，可能被实施重大违法强制退市。 公司触及重大违法强制退市情形，公司股票将被终止上市。 大唐高鸿网络股份有限公司（以下简称"公司"）于 2024 年 7 月 31 日于巨 潮资讯网披露了《关于收到中国证券监督管理委员会立案告知书的公告》（公告 编号：2024-099），因公司涉嫌信息披露违法违规，根据《中 ...

Core Viewpoint - The article discusses the alleged misconduct of former executives at Shanghai Jiao Tong University Angli Co., Ltd. (交大昂立), who are accused of misappropriating company funds through improper insurance transactions, resulting in significant financial losses for the company [2][10]. Group 1: Allegations of Misconduct - Five former executives, including the former chairman and president, are accused of using company funds to purchase insurance policies for themselves and subsequently cashing out the premiums into personal accounts, totaling approximately 16.94 million yuan (about 2.4 million USD) [2][5][9]. - The company has filed a criminal complaint against these executives for "damaging company interests" and has reported the case to the local police, although initial investigations did not lead to formal charges [2][4]. Group 2: Discovery of Irregularities - The irregularities were discovered during a self-audit initiated after a tax authority inquiry in November 2022, which revealed that the company had made significant insurance payments without proper documentation [4][5]. - The company found that in 2018 alone, it had made insurance payments totaling 12.84 million yuan (about 1.8 million USD) without corresponding insurance contracts, raising red flags about the legitimacy of these transactions [4][8]. Group 3: Lack of Compliance and Documentation - The company highlighted the absence of necessary approvals and documentation for the insurance transactions, including a lack of records from the compensation and assessment committee, board resolutions, and public disclosures [2][9]. - The former executives claimed that the insurance purchases and subsequent refunds were part of their compensation, but this assertion lacks legal backing as such remuneration requires board and shareholder approval [5][9]. Group 4: Legal and Regulatory Implications - Legal experts suggest that the actions of the former executives could constitute a breach of fiduciary duty, potentially leading to personal liability for the losses incurred by the company [11][12]. - The article also discusses the regulatory framework surrounding group insurance policies, indicating that refunds should typically be returned to the company rather than individual accounts unless specific legal procedures are followed [14][15].

Group 1 - The company, Jinglan Technology Co., Ltd., received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected violations of information disclosure laws [1][2] - The company is accused of inflating revenue by 162.91 million yuan, which accounted for 14.06% of the reported revenue for the year, through false cost recognition in a project [2][3] - The CSRC plans to impose administrative penalties, including a fine of 4 million yuan on the company and fines on several executives, including 2 million yuan on the former chairman [3][4] Group 2 - The company has committed to improving internal governance and enhancing the quality of information disclosure following the investigation [5][6] - The administrative penalties proposed do not trigger mandatory delisting conditions as per stock listing rules [5]

Core Viewpoint - The company Jinzhou Port Co., Ltd. (referred to as "Delisted Jin Port") is currently in a delisting adjustment period due to serious violations, including financial fraud and illegal information disclosure, leading to the termination of its stock listing [1][2]. Group 1: Company Violations - Delisted Jin Port has been involved in financial fraud for several consecutive years, with regulatory investigations revealing that the company inflated revenue and profits through non-commercial bulk trade activities with seven companies, resulting in a total inflated revenue of over 8.6 billion yuan and inflated profits of nearly 180 million yuan from 2018 to 2021 [2]. - The company also inflated profits in 2022, 2023, and the first quarter of 2024 by 36.1 million yuan, 68.1 million yuan, and 15.4 million yuan respectively, leading to false disclosures in annual reports [2]. - Delisted Jin Port failed to disclose its 2024 semi-annual report on time and had multiple instances of significant omissions in annual reports, along with issues related to related party transactions and non-operating fund occupation [2]. Group 2: Legal and Regulatory Actions - Two vice presidents of Delisted Jin Port were arrested for violating important information disclosure laws, with several other executives also facing criminal measures and administrative penalties [1][4]. - The China Securities Regulatory Commission (CSRC) imposed a fine of 8 million yuan on the company and warned six executives, while the Liaoning Securities Regulatory Bureau fined the company 20 million yuan and penalized 11 executives [4]. - The regulatory actions reflect a "zero tolerance" approach towards financial fraud, aiming to enhance market integrity and protect investor interests through legal and civil remedies [4][5].

Core Viewpoint - The company Weikang Pharmaceutical (300878.SZ) has been penalized 16 million yuan due to non-operational fund occupation by its actual controller and violations in information disclosure [2][3][6]. Group 1: Regulatory Actions and Penalties - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Weikang Pharmaceutical and its actual controller Liu Zhongliang for suspected violations of information disclosure [3]. - The CSRC found that from 2020 to 2023, Liu Zhongliang organized and directed the company to transfer funds under the guise of paying for engineering equipment, which were ultimately transferred to his personal accounts, constituting non-operational fund occupation [3][5]. - The total penalties include 5 million yuan for Weikang Pharmaceutical, 7 million yuan for Liu Zhongliang, and 4 million yuan for five other executives, totaling 16 million yuan [6]. Group 2: Financial Performance and Issues - Weikang Pharmaceutical has experienced a decline in performance since its listing in August 2020, with consecutive losses in 2023 and 2024 [4][10]. - The net profits from 2021 to 2023 were 97 million yuan, 49 million yuan, and a loss of 9 million yuan, respectively [9]. - In 2024, the company reported a loss of 147 million yuan, with a particularly poor performance in the fourth quarter, where revenue was negative 20 million yuan [10][11]. Group 3: Operational Challenges - The company attributes its declining performance to several factors, including reduced demand for prescription drugs due to changes in medical insurance policies and market conditions, increased competition leading to lower gross margins, and a shift in product promotion strategies [10]. - In 2024, Weikang Pharmaceutical's sales expenses were 201 million yuan, accounting for 57.26% of its revenue, while R&D expenses were only 14 million yuan, representing 4% of revenue, a decrease of 66.85% year-on-year [10]. Group 4: Corporate Governance Changes - Due to the fund occupation issues, two executives left their positions, with Liu Zhongliang resigning as chairman and director in May 2024 [7].